Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts-Randomized, Double-blind, Active Controlled and Open-label, Single-arm

Next Previous
X
Search
Trial Profile

Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts-Randomized, Double-blind, Active Controlled and Open-label, Single-arm

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABNCoV2 cVLP based COVID 2019 vaccine AdaptVac (Primary) ; Tozinameran
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Bavarian Nordic

    • Most Recent Events

    • 25 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 22 Oct 2023 This study has been completed in Belgium and Denmark, according to European Clinical Trials Database record.
    • 01 Sep 2023 According to a Bavarian Nordic media release, additional safety data will be report for 6-month post vaccination at a later time point.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top